NHS waiting list for planned treatment falls to lowest level in two years
The NHS waiting list for planned hospital treatment has fallen to its lowest level for two years, figures show.
An estimated 7.39 million treatments were waiting to be carried out at the end of April, relating to 6.23 million patients – down from 7.42 million treatments and 6.25 million patients at the end of March.
These are the lowest figures since March 2023 for treatments and April 2023 for patients.
The news comes after Chancellor Rachel Reeves gave the NHS a cash injection worth an extra £29 billion per year.
Health and Social Care Secretary Wes Streeting said: 'We are putting the NHS on the road to recovery after years of soaring waiting times, by providing record investment and fundamental NHS reform.
'Thanks to our interventions and the hard work of NHS staff, the overall waiting list has now fallen in April for the first time in 17 years – dropping by almost a quarter of a million since we took office.
'This is just the start. We've delivered millions of extra appointments since July, we are pushing on with our mission to get the NHS working for patients once again as we deliver our Plan for Change.'
Within the new NHS figures, the number of longer waits has grown.
Some 1,361 patients in England had been waiting more than 18 months to start routine treatment at the end of April, up from 1,164 in March.
There were 9,258 patients who had been waiting more than 65 weeks to start treatment, up from 7,381 the previous month.
Overall, 190,068 people in England had been waiting more than 52 weeks to start routine hospital treatment, up from 180,242 at the end of March.
The figure had previously fallen for 10 months in a row.
NHS England said that, overall, the average time patients had been waiting for planned treatment fell to the lowest level since July 2022 – 13.3 weeks – despite services facing greater demand.
Meghana Pandit, NHS England's co-national medical director, said NHS staff were working to 'turn the tide for patients waiting for care'.
She said while huge pressure on services remains, 'we are starting to see a real difference across our services – this is just the start of the work we're doing to reform care and deliver improvements for patient'.
The data also showed fewer people are getting a diagnosis of cancer or having it ruled out within four weeks.
A total of 76.7% of patients urgently referred for suspected cancer were diagnosed or had cancer ruled out within 28 days in April, down from 78.9% in March and 80.2% in February.
The Government and NHS England had set a target of March 2026 for this figure to reach 80%.
The proportion of patients who had waited no longer than 62 days in April from an urgent suspected cancer referral, or consultant upgrade, to their first definitive treatment for cancer was 69.9%, down from 71.4% in March.
GPs in England made 264,880 urgent cancer referrals in April, down from 272,165 in March but up year-on-year from 260,516 in April 2024.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
New 10-year strategy aims to get Glaswegians more active
New Physical Activity and Sport Strategy for Glasgow 2025-2035 unveiled (Image: Glasgow Life) A new strategy is aiming to make sport and physical activity a core part of everyday life. Active Glasgow: A Physical Activity and Sport Strategy for Glasgow 2025-2035, developed by Glasgow Life and sector partners, aspires to enhance the lives of Glaswegians through activity and sport. Advertisement The plan, approved by the City Administration Committee, seeks to integrate sport and physical activity into the daily routines of Glaswegians. (Image: Glasgow Life) Read more: MSP praises Glasgow initiative making equipment accessible to everyone It targets health inequalities and promotes diversity, equality, and inclusion, with success measured by a positive increase in activity levels. Changes in environments, practices, and policies will be monitored in addition to evidence-based shifts in activity levels within targeted communities. Various partners, including sports clubs, health services, educational services, and public health organisations, will collaborate on the strategy's implementation. Advertisement The strategy has been deemed essential in light of figures revealed around the state of physical wellbeing in Glasgow. Figures have shown that 34% of adults and 31% of children in Glasgow do not meet the NHS's weekly physical activity guidelines. Bailie Annette Christie, chair of Glasgow Life and Glasgow City Council convenor for culture, sport, and international relations, said: "Physical activity and sport have the power to boost mental and physical wellbeing, unite communities, and transform lives. "This strategy focuses on addressing the issues that prevent people from getting involved in physical activity by offering solutions to help more Glaswegians and visitors to our city get active and experience the benefits of an active lifestyle." Advertisement The strategy aims to make Glasgow a leader in creating an encouraging environment for physical activity. It proposes a single referral point for people who need support to be active and plans to develop the Live Active Exercise Referral Scheme and the Live Well Community Referral Programme. Dr Emilia Crighton, director of public health at NHS Greater Glasgow and Clyde, said: "The health benefits of physical activity and active living are well-known. "Physical exercise is often branded a 'miracle cure', due to the critical role it plays in improving physical and mental wellbeing and helping to address a range of illnesses and health conditions. Advertisement "Creating an environment where physical activity becomes the easy option for people is central to health and wellbeing, and it is at the heart of this strategy. 'The focus on accessibility, availability, existing community assets, and greenspace, together with building confidence and skills for people of all ages, are critical to enabling this city to become an Active Glasgow – and therefore a healthier Glasgow.' The plan also includes widening access to green spaces, recreational, and sports spaces, and ensuring they are safe and welcoming for all. (Image: Glasgow Life) Read more: Glaswegians urged to 'light up the longest day' and help feed hungry children Paul Johnston, chief executive of Public Health Scotland, said: "Implementation of this strategy will transform environments, infrastructure, and services across Glasgow, making it easier for individuals to incorporate movement into their daily lives. Advertisement "Being physically active is hugely beneficial to improving our physical and mental health and contributes towards the prevention of illness and diseases. "We hope this will be the first of many local strategies which will drive the necessary changes to create a healthier, more active Scotland." The Active Glasgow strategy can be read in full on the Glasgow Life website.
Yahoo
an hour ago
- Yahoo
Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer
LUND, SE / / June 13, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback supporting the selection of the 900 µg/kg dose of its CD40 agonist mitazalimab for the planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). This positive regulatory feedback confirms Alligator's dose selection and represents a key milestone in the late-stage development of mitazalimab. "We are very pleased with the FDA's timely and constructive response. This marks an important step forward as we finalize our Phase 3 program for mitazalimab in one of the most aggressive and underserved cancers. We are now in active partnering dialogues aiming to secure the right partner to take mitazalimab into Phase 3," said Søren Bregenholt, CEO of Alligator Bioscience . For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 8:45 a.m. CEST on 13 June 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Alligator Bioscience receives FDA endorsement of mitazalimab Phase 3 dose for pancreatic cancer SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
an hour ago
- Medscape
Symptom and Allergy Load Drives Food Allergy Distress
For adults, children, and caregivers, more symptoms and multiple food allergies and, for adults and caregivers, adrenaline autoinjector prescriptions were linked to more psychological distress. METHODOLOGY: Researchers conducted a cross-sectional online survey involving 1329 adults (mean age, 38.1 years; 70.2% women) and 1373 caregivers (mean age, 37.6 years; 75.1% women) of children with food allergy to identify factors associated with specific types of food allergy‐related psychological distress. Participants reported types of food allergy-related distress experienced by themselves or their children. TAKEAWAY: Female adults (mean difference, -3.74) and female caregivers (mean difference, -5.82; P < .001 for both) were more likely to experience multiple types of food allergy-related psychological distress than male adults. < .001 for both) were more likely to experience multiple types of food allergy-related psychological distress than male adults. In children and caregivers, the likelihood of reporting more types of distress increased with allergy duration, whereas in adults and caregivers, it rose with prescriptions of adrenaline autoinjectors ( P < .001 for all). < .001 for all). Adults, children, and caregivers with a higher number of food allergies, more comorbid conditions, or more symptoms of food allergy were more likely to experience psychological distress ( P < .001 for all). < .001 for all). Adults and caregivers from Australia, Brazil, Canada, and the UK consistently reported higher rates of psychological distress than those from European countries or the US. IN PRACTICE: 'Adults may find it beneficial to learn how to recognize the symptoms of anaphylaxis, enabling them to more accurately assess their level of risk. In families with an allergic child, caregivers require more psychological support when the child is younger,' the authors wrote. SOURCE: R.C. Knibb, PhD, with Aston University, Birmingham, England, was the corresponding author of the study, which was published online in Clinical and Translational Allergy. LIMITATIONS: This study lacked a validated distress scale, and the perceived severity of food allergy was not assessed. Participants were mostly White, women, and university-educated, limiting the generalizability of the findings. Additionally, the online recruitment method and requirement for internet access likely introduced selection bias. DISCLOSURES: This study was funded by Novartis, Aimmune Therapeutics, the National Peanut Board, and the European Academy of Allergy and Clinical Immunology. Some authors reported receiving research funding, grants, personal fees, or honoraria from and having other ties with various organizations and pharmaceutical companies, including some of the funding sources.